Company: TBPH
Filing Date: 2025-04-10
Form Type: DEF 14A
Source: 0001104659-25-033819
Chunk: 50

Company: Theravance Biopharma, Inc.
Filing Date: 2025-04-10
Form: DEF 14A
Chunk 50
---
ham agreed to use approximately 20% of his 2024 after-tax salary to purchase our ordinary shares. These purchases took place periodically at a purchase price per share equal to the closing price of an ordinary share on the Nasdaq Global Market on each purchase date. • Each of our named executive officers was eligible for an annual cash bonus under our performance-based cash bonus program based on our achievement of 2024 corporate goals, which were intended to be motivational and more challenging than we expected to achieve. 32 TABLE OF CONTENTS • Approximately 50% of each of our named executive officer’s 2024 equity compensation was awarded as performance-based RSUs (“PSUs”). The PSUs granted to our named executive officers vest upon the achievement of three share price appreciation targets of increasing difficulty over four years, all of which, if achieved, will reflect strong growth in our share price. 2025 Compensation Decisions The Compensation Committee’s decisions regarding compensation levels and performance incentives for 2025 were intended to continue to align executives’ incentives with the performance of the overall company and their primary area of focus, as well as managing employee-related costs. • Mr. Winningham was not awarded an annual equity grant for 2025 in order to further reduce employee compensation costs in 2025. The Compensation Committee made this decision after considering Mr. Winningham’s suggestion that he forgo his 2025 grant. • For the fourth consecutive year, Mr. Winningham’s salary and target bonus were not increased. • The 2025 corporate bonus plan has been set using pre-established weightings for the goals in each category that reflect key value drivers for us. • 2025 annual replenishment equity awards for our named executive officers (other than Mr. Winningham who did not receive one) were granted with solely time-vested RSUs. 2024 Base Salaries and Annual Incentive Opportunities Base salaries are set to reflect compensation commensurate with the executive’s current position, work experience and contribution. Our goal is to attract and retain high caliber talent for the position and to provide a base wage that is stable and subject to relatively little risk. Salary for the Chief Executive Officer and the other named executive officers is determined based on the underlying scope of their respective responsibilities and their personal experience working at innovative biotechnology and drug development companies and takes into account competitive market compensation data. The base salaries and target bonuses of our named executive officers are generally reviewed annually and adjusted when our compensation committee determines that an adjustment is appropriate. Our named executive officers’